

## 1 SUPPORTING INFORMATION

2 *Construction of strains and plasmids.* All oligonucleotide primer sequences, plasmids, and  
3 strains are given in Table S1. To create RK113, we deleted the endogenous *ccm* operon in *E.*  
4 *coli* BW25113 by P1 transduction. Briefly, P1 phage were grown first in LB media containing 5  
5 mM CaCl<sub>2</sub> and 0.2 % glucose (wt/vol) with the donor strain (RK103 (*I*)). Donor cells were  
6 killed by addition of chloroform and phage were isolated. Dilutions of isolated phage (100 μL)  
7 were incubated with 100 μL of the recipient strain (BW25113) in LB containing 5 mM CaCl<sub>2</sub>  
8 and 100 mM MgSO<sub>4</sub> at 37°C for 30 min. Physical interaction between the phage and cells was  
9 disrupted by addition of 66.7 mM sodium citrate (Fisher), pH 5.5, and the culture was added to 1  
10 mL LB broth and incubated for one hour at 37°C while shaking at 300 rpm. Transductants were  
11 selected by growth on LB + Kan, and cells were purified from P1 phage by repeated streaking on  
12 LB + Kan plates containing sodium citrate. Deletion of the *ccm* operon in RK113 was confirmed  
13 by genomic PCR. To create RK111, we used the pKNOCK system (2). Briefly, the *cyt c*<sub>4</sub>:His6  
14 gene along with the *araC* gene were cloned from pRGK332 (*I*) into pKNOCK-Gm (2). The  
15 *araC* gene was included to serve as the site for homologous recombination with the  
16 chromosome. Cloning was done in *E. coli* S17-1/λ*pir*, and the plasmid was conjugally  
17 transferred to *E. coli* RK103 (*I*). Putative exconjugants were selected for resistance to 10 ug ml<sup>-1</sup>  
18 gentamicin, and correct integration of *cyt c*<sub>4</sub>:His was verified by genomic PCR.

19 *E. coli* strains TB1 and HB101 were used as host strains for cloning. pRGK333 (*I*)  
20 containing the full system I operon (*ccmABCDEFGHI*) was the template for all PCR  
21 amplifications unless otherwise indicated. A plasmid containing *ccmABCDE* ( $\Delta$ *ccmFGH*) was  
22 constructed by PCR amplification of *ccmABCDE* with Ccm\_N-term and Del\_CcmF\_Left, the  
23 product of which was digested, and ligated into BamHI and EcoRI digested pGEX-4T-1 (GE


24 Healthcare) to make pRGK402. To generate the His173Ala, His261Ala, and His303Ala  
25 mutants, short PCR products were amplified using Del\_CcmE\_Right and  
26 CcmF\_His173Ala\_Rev, CcmF\_His261Ala\_Rev, or CcmF\_His303Ala\_Rev. These products  
27 were gel purified and used in a second amplification with CcmH\_XhoI\_Rev using pRGK386 (3)  
28 as template to generate *ccmF*(His173Ala):His6GH, *ccmF*(His261Ala):His6GH, and  
29 *ccmF*(His303Ala):His6GH (His6 refers to a hexahistidine tag at the carboxy terminus of CcmF).  
30 The final, full-length products were ligated into NdeI and XhoI digested pRGK402 to generate  
31 pRGK403, pRGK404, and pRGK405, respectively. A plasmid containing *ccmABCDEGH*  
32 ( $\Delta$ *ccmF*) was constructed by PCR amplification of *ccmGH* with Del\_CcmF\_Right and Ccm\_C-  
33 term primers, the product of which was digested and ligated into EcoRI and NdeI digested  
34 pRGK402 to make pRGK406. For the His491Ala mutant, a short PCR product was generated by  
35 amplifying with CcmF\_His491Ala\_Fwd and CcmF\_6xHis\_NdeI\_Rev. This product was gel  
36 purified and then used in a second amplification with Del\_CcmE\_Right to generate *ccmF*  
37 (His491Ala):His6. The final, full-length product was ligated into the single NdeI site of  
38 pRGK406 to generate pRGK407.

39 To insert *ccmF*:His6, *ccmF*(His261Ala):His6, or *ccmF*(His491Ala):His6 into pRGK330  
40 (*I*) for arabinose-inducible expression in the absence of other *ccm* genes, the corresponding  
41 *ccmF* gene was amplified from pRGK386, pRGK404, or pRGK407, respectively, with  
42 CcmF\_NcoI\_Fwd and CcmF\_6xHis\_PstI\_Rev, digested, and ligated into NcoI and PstI digested  
43 pRGK330 to make pRGK408, pRGK409, and pRGK410. His261Gly, Cys, Tyr, and Met were  
44 generated by amplifying with the appropriate reverse mismatch primer and CcmF\_NcoI\_Fwd to  
45 generate short PCR products. These products were gel purified and used in a second  
46 amplification with CcmF\_6xHis\_PstI\_Rev. His491Gly, Cys, Tyr and Arg were generated by


47 amplifying with the appropriate forward mismatch primer and CcmF\_6xHis\_PstI\_Rev to  
48 generate short PCR products. These products were gel purified and used in a second  
49 amplification with CcmF\_NcoI\_Fwd. The final, full-length products for all site-directed mutants  
50 at His261 and His491 described above were digested with NcoI and PstI and inserted into  
51 pRGK330 to generate pRGK411-418. Each of the final constructs was sequenced to confirm the  
52 mutation.

53         The *ccmF-3* gene from *Shewanella oneidensis* (SO\_0478) was PCR amplified from  
54 genomic DNA, digested, and ligated into the NcoI and PstI sites in pRGK330 to generate  
55 pRGK420. The *ccmF* gene from *Roseobacter denitrificans* (RD1\_3223) was amplified from  
56 genomic DNA, digested, and ligated into the EcoRI and KpnI sites of pRGK330 to make  
57 pRGK424. *Roseobacter denitrificans* genomic DNA was provided generously by the  
58 Blankenship lab. The *ccmF-2* gene from *E. coli* (b4074) was amplified from genomic DNA,  
59 digested, and ligated into the NcoI and XbaI sites of pRGK330 to make pRGK421. The *ccmF*  
60 genes from *Shewanella oneidensis* (SO-0266), *Desulfovibrio vulgaris* (DVU\_1050), and  
61 *Thermus thermophilus* (TTHA1404) were each amplified from genomic DNA with the  
62 appropriate primers and cloned into pCR-Blunt II-TOPO (Invitrogen). From pCR-Blunt II-  
63 TOPO, the *ccmF* gene from *Shewanella oneidensis* was ligated into the NheI and XhoI sites of  
64 pRGK330 to make pRGK419, the *ccmF* gene from *Desulfovibrio vulgaris* was ligated into the  
65 NcoI and XbaI sites to make pRGK423, and the *ccmF* gene from *Thermus thermophilus* was  
66 ligated into the KpnI and NheI sites to make pRGK422. *Desulfovibrio vulgaris* subsp. *vulgaris*  
67 ATCC 29579 and *Thermus thermophilus* ATCC 27634 strains were obtained from ATCC and  
68 cultured according to ATCC recommendations, and genomic DNA was prepared using the  
69 Puregene System Cell and Tissue DNA Isolation Kit (Gentra Systems).







70 **Figure S1.** Peak fitting of the ferrous CcmF UV-visible absorbance spectrum. The fit peaks  
 71 reveal speciation between 6cLS (red) and 5cHS (blue) hemes with a significant fraction being  
 72 5cHS. Assuming that the extinction coefficients at the HS and LS Soret maxima are roughly  
 73 equal, the samples of ferrous CcmF(WT) used in this study comprise approximately 20 % 5cHS  
 74 heme. Based on similarities among the UV-visible spectra and insensitivity of the  $v_3$  ratios to  
 75 [DDM] between 0.48 % and 0.02 %, this speciation is essentially independent of DDM  
 76 concentration.



77 **Figure S2.** Representative heme stain showing cytochrome  $c_4$ :His6 assembly (i.e., heme  
78 attachment) by the indicated CcmF proteins in the presence or absence of 10 mM imidazole.  
79 Arrow indicates 24 kDa holocytochrome  $c_4$ :His6 matured by a functional system I. “pSysIΔF”  
80 denotes a system I deleted for *ccmF*; “c4:His only” denotes an absence of all *ccm* genes; “M”  
81 denotes molecular weight standards (shown is the 28 kDa standard). 100 μg of BPER-isolated  
82 proteins was loaded into each lane for SDS-PAGE prior to heme staining.




83 **Figure S3.** Representative heme stains showing cytochrome *c*<sub>4</sub>:His6 assembly of mutants at  
 84 His261 (A) and His491 (B) in the presence or absence of 10 mM imidazole (as described in  
 85 Figure S1). Arrow indicates 24 kDa holocytochrome *c*<sub>4</sub>:His6 matured by a functional system I.  
 86 Substitutions: A, Ala; G, Gly; C, Cys; Y, Tyr; M, Met; R, Arg. The dash denotes the negative  
 87 control condition (absence of CcmF) and “wt” denotes wild-type CcmF. “M” denotes molecular  
 88 weight standards (shown is the 28 kDa standard). 100 μg of BPER-isolated proteins was loaded  
 89 into each lane for SDS-PAGE prior to heme staining.




90 **Figure S4.** Coomassie stain (A) and corresponding heme stain (B) after SDS-PAGE of  
 91 CcmF:His6 from *E. coli* (*Ec*), *Thermus thermophilus* (*Tt*; Deinococcus group), *Desulfovibrio*  
 92 *vulgaris* (*Dv*), *Roseobacter denitrificans* (*Rd*), *Shewanella oneidensis* (*So*), *Shewanella*  
 93 *oneidensis* CcmF-3 (*So-F3*), and *E. coli* CcmF-2 (*Ec-F2*). Arrows indicate full-length 54 kDa  
 94 CcmF:His6 and free heme at the SDS-PAGE dye front. Note that some of the *So*-CcmF3 and  
 95 *Ec*-CcmF2 aggregate at approximately 117 kDa, possibly a dimeric form, under the conditions of  
 96 SDS-PAGE used. Additionally, note that for *Dv*, *So*-CcmF3 and *Ec*-F2, some heme is retained  
 97 in the full length protein and/or in the higher molecular weight forms. For each of the proteins  
 98 analyzed, heme was found to be non-covalent as determined by pyridine hemachromagen (data  
 99 not shown). Thus, *Dv*, *So*-CcmF3 and *Ec*-F2 may bind heme in a partially SDS-resistant,  
 100 although non-covalent, manner. 30  $\mu$ g of purified hexahistidine-tagged protein was analyzed for  
 101 each.





102 **Figure S5.** Redox titration of the CcmF *b*-heme with alternate redox dyes. Spectra collected  
 103 during reduction of CcmF *b*-heme with resorufin (A) or safranin O (B). Arrows indicate the  
 104 direction of changes in absorption during the course of the titration. The decreases in absorbance  
 105 at 534 nm and 572 nm in (A) are due to reduction of resorufin. In (B), the decrease in  
 106 absorbance at 412 nm and the increase in absorbance at 426 nm are indicative of reduction of the  
 107 CcmF *b*-heme, and the decrease in absorbance at 532 nm is due to reduction of safranin O. Note  
 108 that the dye resorufin ( $E_m = -50$  mV) (4) is completely reduced before reduction of the CcmF *b*-  
 109 heme, while the CcmF *b*-heme is completely reduced before reduction of safranin O ( $E_m = -280$   
 110 mV) (4). This indicates that the relative midpoint potential of the CcmF *b*-heme is in between  
 111 that of resorufin and safranin O. Conditions: 20 mM Tris-HCl, pH 7, 100 mM NaCl, 0.02 %  
 112 DDM.



113 **Figure S6.** Redox titration of the CcmF *b*-heme in high DDM (1.2 %). Spectra collected during  
 114 a reductive titration of CcmF *b*-heme with Nile blue chloride ( $E_m = -116$  mV) (4) (A) and the  
 115 corresponding linear Nernst plot (B). Arrows in (A) indicate the direction of changes in  
 116 absorbance during the course of the titration. In (B),  $[25 \text{ mV} \ln (b\text{-heme}_{\text{red}}/b\text{-heme}_{\text{ox}})]$  was used  
 117 for the one-electron reduction of heme and  $[12.5 \text{ mV} \ln (\text{dye}_{\text{red}}/\text{dye}_{\text{ox}})]$  was used for the two-  
 118 electron reduction of dye, where  $b\text{-heme}_{\text{red}}/b\text{-heme}_{\text{ox}}$  and  $\text{dye}_{\text{red}}/\text{dye}_{\text{ox}}$  represent ratios of the  
 119 molar concentrations of the reduced and oxidized forms of the *b*-heme and the dye, respectively.  
 120 The reduction potential in 1.2 % DDM was substantially more positive ( $E_m = -110 \pm 4$  mV) than  
 121 in 0.02 % DDM. Conditions: 20 mM Tris-HCl, pH 7, 100 mM NaCl, 1.2 % DDM.

122 **SUPPORTING INFORMATION REFERENCES**

- 123 (1) Feissner, R. E., Richard-Fogal, C. L., Frawley, E. R., Loughman, J. A., Earley, K. W.,  
124 and Kranz, R. G. (2006) Recombinant cytochromes c biogenesis systems I and II and  
125 analysis of haem delivery pathways in *Escherichia coli*. *Mol Microbiol* 60, 563-577.
- 126 (2) Alexeyev, M. F. (1999) The pKNOCK series of broad-host-range mobilizable suicide  
127 vectors for gene knockout and targeted DNA insertion into the chromosome of gram-  
128 negative bacteria. *Biotechniques* 26, 824-826.
- 129 (3) Richard-Fogal, C. L., Frawley, E. R., Bonner, E. R., Zhu, H., San Francisco, B., and  
130 Kranz, R. G. (2009) A conserved haem redox and trafficking pathway for cofactor  
131 attachment. *Embo J* 28, 2349-2359.
- 132 (4) Clark, W. M. (1960) *Oxidation-Reduction Potentials of Organic Systems*, Waverly Press,  
133 Baltimore, MD.